ICYMI: Wall Street Journal highlights dangers of counterfeit medicines entering the United States through drug importation
This week, the Wall Street Journal took a closer look at the very real threat drug importation poses.
This week, the Wall Street Journal took a closer look at the very real threat drug importation poses.
This week, the Wall Street Journal took a closer look at the very real threat drug importation poses, detailing how such schemes expose Americans to dangerous counterfeit medicines. The reporter put a human face to the threat, describing how a young man lost his life after unknowingly taking a counterfeit medicine laced with deadly counterfeit fentanyl.
Tragedies like this are why the U.S. Food & Drug Administration (FDA) has taken great strides to stem the flow of counterfeits into the United States through fake online pharmacies. In June and August, for example, the FDA cracked down on more than 50 websites known to be illegally selling unapproved or fake versions of opioids. This progress is a step in the right direction, but more needs to be done to protect Americans. Here are a few key points on the complexities the article raises:
Far too many American lives are put at risk by the consumption of counterfeit medicines purchased online and illegally shipped to the United States. Proposals to allow drug importation schemes unnecessarily increase the potential danger to Americans and impose a large burden on law enforcement officials already tasked with helping address the opioid epidemic. Policymakers should think twice before supporting a policy that exposes their constituents to dangerous counterfeits.
Learn more at PhRMA.org/Importation.